In the Maternal Fetal Medicine Units (MFMU) Network predictive model, increasing body mass index (BMI) reduces the likelihood of successful vaginal birth after cesarean (VBAC). We sought to evaluate VBAC success rates according to BMI group and to compare observed success with predicted success based on the antepartum MFMU calculator. STUDY DESIGN: This was a retrospective cohort study of singleton pregnancies ! 37 weeks undergoing trial of labor after cesarean (TOLAC) at an academic tertiary care center. Exclusion criteria were major anomalies, fetal demise, and more than one previous cesarean. Data were collected via individual chart review and analyzed by maternal BMI category at delivery: lean (< 25.0 kg/m 2 ), overweight (25.0-29.9 kg/m 2 ), Class I obese (30.0-34.9 kg/m 2 ), Class II obese (35.0-39.9 kg/m 2 ), Class III obese (>40.0 kg/m 2 ). Primary outcome was VBAC success. Secondary outcomes were adverse maternal and neonatal outcomes. Predicted success was calculated using the MFMU calculator. Groups were compared using student t-test, chisquared, and ANOVA. P < 0.05 was considered significant. RESULTS: Of 1397 TOLACs performed between 2011-2017, 1039 met study criteria and were analyzed. 514(50%) were obese, 211(21%) hypertensive, and 103(10%) diabetic. BMI groups had similar tobacco use and history of cesarean for arrest of labor (p ¼ .1). Hypertension, diabetes, black race, and maternal age increased with BMI (p < .001 for all). VBAC success decreased with increasing BMI (p ¼ .001). Observed and predicted VBAC success were similar for lean and overweight women (p ! .1), but observed success was higher than predicted for Class I, II, and III obese women (p .01, see Figure) . Uterine rupture rate was 1% overall. Maternal and neonatal adverse outcomes were similar among BMI groups (p ! 0.2 for all, see Table) . CONCLUSION: While VBAC success decreased with increasing maternal BMI, obese women had greater success than predicted. The impact of obesity on VBAC success may be lower than predicted by the MFMU model. OBJECTIVE: Circulating inflammatory factors may predispose to blood-brain-barrier impairment and neuroinflammation in preeclampsia, but human data is limited. We tested the hypothesis that peripheral inflammatory mediators (complement factors and cytokines) access cerebrospinal fluid (CSF) through a leaky blood-brainbarrier in preeclampsia. STUDY DESIGN: Prospective case-control study of pregnant women with a non-anomalous gestation >24 weeks, with indicated spinal anesthesia or combined spinal epidural analgesia. Women were enrolled in three groups: 1) Healthy controls; 2) Chronic or gestational hypertension and; 3) Preeclampsia with or without severe features. Blood and urine were collected before delivery, with CSF collected during spinal placement. In blood and CSF, we measured biomarkers using enzyme linked immunosorbent assays: albumin, C5a, C5b-9, TNF-a, and IL-6. Albumin and complement factors were also measured in urine. The CSF/plasma albumin quotient was used to assess blood-brain-barrier integrity. Clinical data was abstracted from the medical record. Differences were assessed by ANOVA, chi-squared test, or test of medians, with a¼0.05.
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RESULTS:
In total, 48 subjects enrolled (16 per arm) and summary characteristics are detailed in Table 1 . Plasma, urine and CSF measurements for albumin, C5a, C5b-9, TNF-a, and IL-6 are shown in Table 2 . Preeclampsia was associated with increased plasma levels of terminal complement effector C5b-9 (membrane attack complex) and pro-inflammatory cytokine IL-6. Marked urinary excretion of C5b-9 in preeclampsia (p<0.001) confirmed end-organ effects in the kidney. Despite systemic complement activation and end-organ injury in preeclampsia, C5b-9 remained undetectable in CSF. Levels of IL-6 were detectable in CSF, but they did not increase in conjunction with rising plasma levels in preeclampsia. Likewise, Poster Session III ajog.org albumin was detectable in CSF, but the CSF/plasma albumin quotient did not increase in preeclampsia (p¼0.78, vs. controls). Moreover, CSF albumin levels were not increased in the subset of 8 preeclampsia subjects with severe features [median 16.0 mg/dl, interquartile range (12.5-17.0)]. CONCLUSION: We find that the integrity of the blood-brain-barrier is maintained in preeclampsia despite evidence of systemic inflammation and terminal complement activation.
599 Pregnancy-associated atypical hemolytic uremic syndrome: some answers OBJECTIVE: Pregnancy-associated atypical hemolytic uremic syndrome (p-aHUS) is a rare and life-threatening disorder, which may be mistaken for hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome. We sought to identify laboratory features that differentiate p-aHUS from HELLP.
STUDY DESIGN: PubMed was searched (inception to Sep '17) with MeSH terms "pregnancy" AND "hemolytic-uremic syndrome", to identify cases of atypical hemolytic uremic syndrome in pregnancy or postpartum. 395 articles were screened, with p-aHUS cases excluded if diagnosis was made <20 weeks gestation (n¼3), >2 weeks postpartum (n¼2) or following miscarriage (n¼3). HELLP cases (>20 weeks gestation) were identified from our institutional database (Jan '13 e Dec '17). For recurrent p-aHUS (n¼2) or HELLP (n¼4), the index pregnancy was selected. Laboratory data were abstracted as peak values [aspartate transaminase (AST, U/L); creatinine (mg/dl); lactate dehydrogenase (LDH, U/L)] or nadir values [hemoglobin (g/dl); platelet count (k/ml)] during hospital course. Data were presented as median (interquartile range), with analysis by test of medians, a¼0.05. Receiver operating characteristic (ROC) curves were used to assess individual lab parameters for diagnosis of p-aHUS. RESULTS: We identified 29 unique cases of p-aHUS and 44 unique cases of HELLP syndrome. Women with p-aHUS were more often younger (27.8AE6.6 vs. 35.6AE3.5 years, p<0.001) and nulliparous (89% vs. 46%, p¼0.001), but gestational age at delivery was no different (35.4AE3.5 vs. 35.9AE4.3 weeks, p¼0.64). Hemoglobin and platelet count were lower, and LDH and creatinine levels markedly higher, in p-aHUS vs. HELLP (Table 1) . AST levels did not differ between groups. Levels of creatinine and LDH were most useful for diagnosis of p-aHUS, with area under the ROC curve 0.98 (0.95-1.0) and 0.94 (0.89-0.99), respectively (Figure 1 ). The optimal cut-points to diagnose p-aHUS (vs. HELLP) was creatinine !1.9 mg/dl (+ likelihood ratio 21.2) and LDH !1850 U/L (+ likelihood ratio 27.4). The combination of creatinine !1.9 mg/dl and LDH !1000 U/L was seen in 91% of p-aHUS cases and 0% of HELLP cases (p<0.001). CONCLUSION: We find that standard laboratory data differentiate paHUS and HELLP syndrome. Creatinine and LDH levels are most discriminatory, and when both are markedly elevated the diagnosis of p-aHUS is likely.
